AlloCure Inc. Begins Phase 2 Clinical Trial in Acute Kidney Injury
9/4/2012 10:01:06 AM
BURLINGTON, Mass.--(BUSINESS WIRE)--AlloCure, Inc. today announced that it has initiated a phase 2 clinical trial of AC607, the company’s mesenchymal stem cell therapy, as a potential treatment for acute kidney injury (AKI). The randomized, double-blind, placebo-controlled, multi-center trial, designated ACT-AKI (AC607 Trial in Acute Kidney Injury) (NCT01602328), will enroll 200 cardiac surgery subjects at leading tertiary care centers in the United States.
comments powered by